Related Experiment Videos
Nicotinic receptor abnormalities in Alzheimer's disease
J Court1, C Martin-Ruiz, M Piggott
1Joint MRC Newcastle University Centre Development in Clinical Brain Aging, Institute for the Health of the Elderly, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom.
Biological Psychiatry
|March 7, 2001
Summary
Alzheimer's disease significantly reduces high-affinity nicotinic acetylcholine receptors, primarily affecting alpha4 subunits in the cortex. These changes in nicotinic receptors contribute to Alzheimer's symptoms and neuropathology.
Area of Science:
- Neuroscience
- Neuropathology
- Pharmacology
Background:
- Alzheimer's disease (AD) is characterized by a loss of cortical nicotinic acetylcholine receptors (nAChRs).
- This deficit is particularly notable for high-affinity nAChRs, with reported losses ranging from 20-50%.
Purpose of the Study:
- To investigate the specific changes in nAChR subunits and binding in the brains of Alzheimer's disease patients.
- To differentiate AD-related nAChR changes from those occurring during normal aging.
Main Methods:
- Immunochemical analyses were used to assess protein expression of nAChR subunits (alpha4, alpha3, beta2, alpha7).
- Radioligand binding assays ([125I]alpha-bungarotoxin, [3H]nicotine) were employed to measure receptor binding in cortical, thalamic, and striatal regions.
Main Results:
- A significant loss of alpha4 nAChR subunits (30-50%) was observed in the cortex, with some individuals showing modest alpha3 reductions (25-29%).
- Cortical alpha7 protein and [125I]alpha-bungarotoxin binding showed less extensive decline (0-40%) compared to alpha4 loss.
- Reduced [3H]nicotine binding was found in the striatum, independent of neuroleptic medication, and a trend for reduced binding was seen in the thalamus.
Conclusions:
- The observed changes in nAChRs, especially the loss of alpha4 subunits, are distinct in Alzheimer's disease compared to normal aging.
- These alterations in nicotinic acetylcholine receptors likely play a role in the clinical manifestations and neuropathology of Alzheimer's disease.